Filing Details

Accession Number:
0001491519-19-000001
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-01-25 14:49:18
Reporting Period:
2019-01-23
Accepted Time:
2019-01-25 14:49:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
896747 American Bio Medica Corp ABMC Pharmaceutical Preparations (2834) 141702188
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1491519 Chaim Davis 80 Brainard Road
West Hartford CT 06117
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2019-01-23 38,993 $0.08 132,536 No 4 A Direct
Common Shares Acquisiton 2019-01-23 500,000 $0.10 2,449,915 No 4 P Indirect By Revach Fund, LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 P Indirect By Revach Fund, LP
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Non-Statutory Stock Option Acquisiton 2013-04-26 50,000 $0.18 50,000 $0.18
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
50,000 2014-04-26 2023-04-26 No 4 J Direct
Footnotes
  1. 38,993 shares of restricted stock were issued to Davis as compensation for his attendance at a meeting of the Company's Board of Directors held in January 2019. This stock issuance is in accordance with the director compensation structure approved by the Company's Board of Directors on March 22, 2018 (as indicated in the Company's Proxy Statement filed with the Commission on April 20, 2018).
  2. The volume weighted average price of the Company's common shares for the 10 days preceding the issuance was $0.0833 per share.
  3. These restricted shares of common stock were issued in connection with a private placement of up to 2,000,000 units of common stock as disclosed in a Current Report on Form 8-K filed with the Commission on December 24, 2018. Due to a technical delay, the actual issuance of the shares was not affected until January 25, 2019.
  4. The restricted common shares were issued in connection with a private placement completed on December 24, 2018. The Revach Fund, LP was one of the accredited investors who participated in the private placement. 500,000 units were purchased at $0.10 per share; resulting in a total purchase price of $50,000. Davis is a managing member of Revach Group, LLC which operates as the general partner for the Revach Fund,LP. Davis serves as the Chairman of the Board of the Company.
  5. The price per unit in the private placement was $0.10 per share.
  6. The common shares are in the name of Revach Fund, LP. The reporting person (Davis) is a managing member of Revach Group, LLC which operates as the general partner for the Revach Fund, LP.
  7. This non-statutory stock option was previously reported on a Form 3 filed by Davis on April 19, 2018.This stock option is being re-stated on this Form 4. It is not a new award.